BioVie Inc. (NASDAQ:BIVI – Get Free Report) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, a decrease of 44.0% from the December 15th total of 2,090,000 shares. Based on an average daily trading volume, of 6,120,000 shares, the days-to-cover ratio is currently 0.2 days.
Institutional Trading of BioVie
A hedge fund recently bought a new stake in BioVie stock. Sanders Morris Harris LLC acquired a new position in BioVie Inc. (NASDAQ:BIVI – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 40,000 shares of the company’s stock, valued at approximately $85,000. Sanders Morris Harris LLC owned about 0.23% of BioVie as of its most recent filing with the Securities and Exchange Commission. 4.59% of the stock is owned by hedge funds and other institutional investors.
BioVie Stock Performance
BIVI stock traded up $0.21 during mid-day trading on Wednesday, hitting $2.22. The company had a trading volume of 883,415 shares, compared to its average volume of 1,299,666. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10. The stock’s fifty day moving average price is $2.62 and its two-hundred day moving average price is $2.09. The firm has a market cap of $39.44 million, a PE ratio of -0.19 and a beta of 0.49.
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Further Reading
- Five stocks we like better than BioVie
- What is Put Option Volume?
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- The Most Important Warren Buffett Stock for Investors: His Own
- How Do Stock Buybacks Affect Shareholders?
- What Are Some of the Best Large-Cap Stocks to Buy?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
